Overview

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

Status:
Terminated
Trial end date:
2020-02-10
Target enrollment:
Participant gender:
Summary
This study will be a randomized, single-blind, placebo-controlled, single-ascending dose (SAD), sequential group study. It is a SAD study in healthy Non-Asian subjects (Part 1) and healthy Japanese subjects (Part 2) to assess the safety and tolerability of AZD6615 and to characterize the pharmacokinetics (PK) of AZD6615.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Parexel